Till date, only four medications including three acetylcholinesterase (AChE) inhibitors (donepezil, rivastigmine and galantamine) and N-methyl-d-aspartate (NMDA) receptor antagonist (memantine) are approved by the United States FDA for the treatment of cognitive impairment and dysfunction in the progression of AD. Here, ACHE is linked to Cognitive impairment.